Philips Joins Forces with the American Telemedicine Association to Further Commitment to Telehealth

June 19, 2020

Philips recently announced it has once again joined forces with the American Telemedicine Association (ATA) to help further the adoption of telehealth across the industry, demonstrating its commitment to connecting care across acute, post-acute, and home care settings.

Philips said the continued collaboration spotlights the growing adoption and momentum in telehealth amidst COVID-19, and the need to convey the exponential shift to telehealth capabilities.

The COVID-19 pandemic has increased the share of Americans participating in telehealth from 11% in 2019 to 46% today, with healthcare systems reporting a 50 to 175-fold increase in telehealth volume compared to pre-pandemic levels [1]. As the world begins to move from the first wave of reactive care, into a more proactive phase and beyond, virtual care solutions are supporting the recovery of COVID patients as they transition through their care journey, and non-COVID patients as they return to elective surgeries, diagnoses, prevention and treatments that have been put on hold since the onset of the pandemic.

“There is no better time for Philips to team with the ATA. Philips is creating proactive, AI-powered solutions to improve patient monitoring, precision diagnosis, and clinical workflows at every point along the continuum. This directly aligns with our vision for telehealth — to drive the transformation of health by integrating virtual care from the hospital to physician offices and the home,” said Ann Mond Johnson, CEO, the ATA. “Major industry players like Philips joining the ATA reconfirms the importance of telehealth and creates important new opportunities to deliver quality care whenever and wherever it’s needed.”

“Philips has been a leader in telehealth across acute care and post-acute care settings in the hospital and in the home for over three decades, helping health systems deploy and scale telehealth solutions to help improve patient outcomes, enhance patient and staff experience and lower care costs,” said Roy Jakobs, Chief Business Leader Connected Care, member of the Executive Committee at Royal Philips. “Our alignment with ATA will help promote strong  growth and faster adoption of telehealth and policy changes escalated during the COVID crisis as we pivot to innovate ‘virtual first’ strategies to support hospitals, payers, and patients across care settings, including digital health technologies to support healthy living in the home.”

 

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.